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SUMMARY 8 
Objectives: To determine if serum cardiac troponin I (cTnI) concentrations measured with both a first 9 
generation assay (FG-cTnI) and a high-sensitivity assay (hs-cTnI) were greater in dogs with generalized 10 
seizures than in controls and to identify any clinical variables associated with cTnI concentrations.  11 
Methods: This prospective study investigated 30 dogs following generalized seizures and 30 healthy 12 
controls. Serum cTnI concentrations were measured using two commercially available assays and the 13 
correlation of clinical factors with concentrations was examined.  14 
Results: Serum concentrations (median [range]) were higher in dogs after a seizure compared to 15 
controls when measured by both assays (FG-cTnI (0.07, [0.02-3.05] vs 0.05 [0.02-0.13] ng/mL; 16 
p=0.014) and hs-cTnI (0.03 [0.01-1.92] vs 0.02 [0.01-0.05] ng/mL; p<0.001)). The predictors most 17 
significantly influencing cTnI were an increasing number of seizures (p<0.001) and increasing age 18 
(p<0.001). Both predictors were positively associated with increasing concentrations of troponin I. 19 
Clinical significance: Serum cTnI concentrations were significantly elevated in canine patients with 20 
generalized seizures when compared to controls and concentrations were higher in dogs that 21 
experienced more seizures. This association may indicate that generalized seizures are associated with 22 
damage to the myocardium. 23 
Keywords: epilepsy, death, biomarker, myocardial damage 24 
Introduction  25 
Seizures have a dramatic effect on the autonomic nervous system and people with epilepsy have an 26 
increased risk of sudden unexpected death; termed “Sudden Unexpected Death in Epilepsy” or SUDEP 27 
(Tigaran et al. 2003, Jansen & Lagae 2010). Seizures can lead to short-term alteration of cardiac rhythm, 28 
intracardiac conduction, apnoea and cardiac ischaemia in people (Alehan et al. 2009, Velagapudi P et 29 
al. 2012). It has been suggested that an increased number of generalized seizures leads to an increased 30 
risk of SUDEP (Ryu et al. 2015, Scorza et al. 2016). In rats with experimentally induced seizures, 31 
plasma cardiac troponin I (cTnI) concentrations are elevated following seizures (Metcalf et al. 2009, 32 
Bealer et al. 2010). This was hypothesized to be a result of seizure-induced cardiac myofilament damage 33 
and the authors suggested routinely measuring cTnI concentrations following seizure activity (Metcalf 34 
et al. 2009). It has also been suggested that human epileptic patients at risk of SUDEP should have 35 
serum troponin concentrations measured following a seizure (Dupuis et al. 2012). Known SUDEP risk 36 
factors include an increased number and frequency of seizures, as well as an increased number of anti-37 
epileptic medications (Lhatoo et al. 2015, Ryu et al. 2015). 38 
Seizure activity may lead to increased sympathetic nervous discharge, secretion of adrenaline and 39 
noradrenaline, and reduced parasympathetic activity in human patients (Blumhardt et al. 1986, Tigaran 40 
et al. 2003, Mayer et al. 2004, Velagapudi et al. 2012). It has been suggested that the resultant increase 41 
in heart rate, blood pressure (BP) and myocardial contractility collectively increase myocardial oxygen 42 
demand (Alehan et al. 2009). Therefore, it is possible that prolonged seizure activity might impose a 43 
perfusion/demand mismatch of sufficient severity to produce sub-endocardial ischaemia (Tigaran et al. 44 
2003). There is also evidence to suggest that direct neural connections to the heart can produce cardiac 45 
necrosis lesions in dogs with neurological disease as catecholamines reaching the heart directly via 46 
neural connections may be much more toxic than those reaching the heart via the bloodstream (Kolin 47 
& Norris 1984, Samuels 2007). 48 
In dogs, measurement of cTnI concentrations can be used to detect myocardial cell injury caused by a 49 
variety of causes, including cardiac disease such as mitral valve disease, dilated cardiomyopathy, sub-50 
aortic stenosis and pericardial disease (Oyama & Sisson 2004, Spratt et al. 2005), and noncardiac 51 
disease such as pyometra (Hagman et al 2007), snake bites (Pelander et al 2010), renal failure (Sharkey 52 
et al 2009), pancreatitis (Serra et al 2010), canine babesiosis (Lobetti et al. 2002), ehrlichiosis (Diniz 53 
et al. 2008), immune-mediated haemolytic anaemia (Gow et al. 2011), parvoviral enteritis (Kocaturk et 54 
al. 2012), leishmaniasis (Silvestrini et al. 2012), dirofilariosis (Carretón et al. 2014) and gastric dilation-55 
volvulus (Schober et al 2002). There is little published information on the association of serum cTnI 56 
concentration and naturally occurring seizures in dogs, other than isolated case reports (Kent et al. 2010, 57 
Snyder et al. 2010, Navarro-Cubas et al. 2011, Motta & Dutton 2013), an oral presentation describing 58 
a series of cases (Kim et al. 2012) and one study (Dutton et al. 2016). It has been shown that cTnI 59 
concentrations in patients with cardiogenic syncope are significantly increased as compared with 60 
epileptic or vasovagal patients, however overlap in levels between groups decreases the discriminatory 61 
power of the test for individual dogs (Dutton et al. 2016). No studies have evaluated cardiac troponin 62 
concentrations in a population of dogs with seizures that have no evidence of underlying cardiac or 63 
metabolic disease and compared them to a healthy control population of dogs. It is important to have 64 
information concerning the response of cTnI concentrations following a seizure, to enable correct 65 
interpretation of serum concentrations obtained from patients following a paroxysmal event (such as a 66 
seizure or syncopal episode).  67 
The primary aim of the current study was to compare serum cardiac troponin I concentrations in dogs 68 
following generalized seizures to concentrations obtained from an age matched control population of 69 
healthy dogs.  Secondary aims of the study included identifying whether clinical variables, such as age 70 
and seizure number, were associated with serum troponin concentrations and comparing troponin 71 
concentrations obtained using different cardiac troponin assays. We hypothesized that dogs with 72 
generalized seizures would have higher circulating serum cardiac troponin I concentrations, compared 73 
to control dogs.  74 
Materials and Methods 75 
The study protocol was approved by the University of Cambridge ethical review committee.  76 
Dogs with generalized seizures and healthy controls were prospectively and consecutively recruited at 77 
two referral centres between February 2011 and May 2013. The dogs with seizures included newly 78 
diagnosed dogs and those already receiving treatment. To be included as a case a dog must have 79 
experienced a generalized seizure within seven days of presentation and undergone full cardiac 80 
investigations, including BP measurement, electrocardiography (ECG) and echocardiography without 81 
a cardiac abnormality being discovered. Dogs had to be free from other disease likely to lead to altered 82 
serum troponin concentration such as pancreatitis, immune-mediated haemolytic anaemia and renal 83 
insufficiency, based on history, clinical examination, USG measurement, complete blood count, serum 84 
biochemistry and electrolytes. Dogs were excluded if they showed evidence of renal insufficiency 85 
(based on elevated serum creatinine concentrations (>150 µmol/L) and low urine specific gravity (USG) 86 
measurement (<1.030)), metabolic disorders that could have caused the seizures (hypocalcaemia or 87 
hypoglycaemia), or had a history of recent trauma or intoxication.  88 
Healthy control animals consisted of staff pets undergoing blood sampling for screening before 89 
vaccination, blood donation or elective surgery. They had to have no abnormalities detected on full 90 
clinical, including neurological, examination. They had no history of seizures and were free of any 91 
disease likely to lead to elevated serum cTnI concentrations. They also had to be free of cardiac disease 92 
based on clinical examination, BP, ECG and echocardiography.  93 
Signalment (breed, age, sex, neutered status, bodyweight), history (including time since seizure, in 94 
hours, until blood sampling) and current medication (yes/no) were recorded. For the patients with 95 
seizures, the number of seizures during the seven days prior to presentation and seizure length in 96 
minutes (if more than one seizure had occurred, then the average seizure length) were noted. Full 97 
neurological examination was performed.  98 
Fasted blood samples for measurement of creatinine concentration (µmol/L) were collected from all 99 
dogs and analysed within 24 hours. Blood was collected into 1 mL serum gel tubes and separated by 100 
centrifugation 30 minutes after being left to stand at room temperature. Serum was then chilled at 4ºC 101 
for up to 12 hours before transportation at ambient temperature to a commercial laboratory (Carmichael 102 
Torrance Diagnostic Services (CTDS) Ltd, W Yorks) for analysis. Free catch urine samples were 103 
obtained the same day as blood sampling and USG measured. Laboratories were blinded to patient 104 
history.  105 
Samples analysed using the first generation cardiac troponin I assay (FG-cTnI) were handled as 106 
described for serum creatinine and analysed using a previously described chemiluminescent 107 
immunoassay systema (O’Brien et al. 2006). The cTnI was detected using an enzyme-conjugated 108 
polyclonal anti-troponin I antibody following protein binding onto beads coated with murine anti-109 
troponin I antibody, using Immulite® Analyser. Both antibodies recognise epitopes between amino 110 
acids 33 and 110 of cTnI. Sample handling for the high sensitivity cardiac Troponin I assay (hs-cTnI) 111 
involved collecting blood into 1 mL plain tubes. Plain tube samples were separated by centrifugation 112 
immediately after clotting. The serum was then stored for up to 12 hours at -18ºC before transportation 113 
in frozen cool packs to a commercial laboratory (IDEXX Laboratoriesb, Wetherby). The high-sensitivity 114 
assay (AccuTnI® assay) is a two-site sandwich immunoassayᶜ which detects free and complexed 115 
troponin. The assay uses two mouse-derived monoclonal antibodies directed against 24-40 and 41-49 116 
amino acid sequences of cTnI. This assay has been reported (Adin et al. 2006, Hezzell et al. 2012) and 117 
validated (Oyama & Solter 2004) previously for canine samples. The laboratory reference range was 118 
cTnI < 0.15 ng/mL for the FG-cTnI assay and   0.07 ng/mL for the hs-cTnI assay. The assays’ lower 119 
limits of detection (LOD) were 0.02 ng/mL (FG-cTnI) and 0.01 ng/mL (hs-cTnI). Samples for 120 
measuring serum cTnI concentrations by both methods were taken from patients at presentation. For 121 
patients with seizures, cardiac investigations occurred prior to general anaesthesia (GA), except any 122 
difficult to control status epilepticus (SE) patients, which had cardiac investigations delayed until 24 123 
hours following GA. Systolic BP (mmHg) using a Doppler device was measured according to an 124 
established protocol (Brown et al. 2007). Five readings were taken and the mean calculated. 125 
Electrocardiography used a routine six-lead ECG machine (Esaote P80 Power or Seca CT8000P), with 126 
a period of acclimatisation beforehand. Six limb leads were recorded simultaneously for a minimum of 127 
20 consecutive RR intervals, at a paper speed of 50 mm/second, gain of 10 mm/mV.  128 
Patients underwent full 2D echocardiographic examination without sedation, according to published 129 
recommendations (Thomas et al. 1993) using phased array probes (1.5-11 MHz) with harmonic imaging 130 
(Esaote Piemedical MyLab 40 Vet or Vivid S6 echocardiography machines). An ECG was recorded 131 
simultaneously. Full M-mode, colour and spectral Doppler studies were recorded and analysed. All 132 
cardiac investigations were performed by the same resident in cardiology, working under the 133 
supervision of a Royal College of Veterinary Surgeons (RCVS) specialist in veterinary cardiology.  134 
Dogs with suspected seizures underwent appropriate imaging. Magnetic resonance imaging (MRI) 135 
scans (0.25 T; Vet-MR Grande, Esaote) with gadolinium contrast were obtained in three planes of 136 
orientation (dorsal, sagittal and transverse) under GA. Pre- and post-contrast T1-weighted and T2-137 
weighted images were acquired. In some cases, additional sequences (pre- and post-contrast FLAIR, 138 
gradient echo T2* and STIR) were carried out to better define the underlying brain pathology. 139 
Additional tests, such as Toxoplasma and Neospora serology, were performed by the attending clinician 140 
depending on the individual case. All neurological examinations were performed by European College 141 
of Veterinary Neurology board-certified neurologists or their residents. Definitive diagnosis of the 142 
cause of seizures was made by evaluation of all contributing evidence with idiopathic epilepsy being a 143 
diagnosis of exclusion (Berendt et al. 2015). Dogs with idiopathic epilepsy were younger than six years 144 
at seizure onset, had recurrent seizures and were normal on inter-ictal neurological and laboratory 145 
examination. They had no evidence of neurological disease, other than seizures during their lives up 146 
until presentation. Dogs were grouped into healthy controls (group C) or those with generalized seizures 147 
but no evidence of cardiac disease (group S).  148 
Data were analysed using commercially available softwarede. Continuous variables were checked to see 149 
whether they came from a normal distribution using a Shapiro-Wilk test. In descriptive statistics 150 
continuous variables from a normal distribution are reported as mean (+/- SD) those not from a normal 151 
distribution as median (range). Cardiac troponin I concentrations below the LOD of the assays used 152 
were ascribed the value of the limit of detection; 0.01 ng/ml for the hs-cTnI assay, and 0.02 ng/ml for 153 
the FG-cTnI assay.  154 
Simple linear regression was performed with cTnI concentration as the dependent variable. The 155 
following predictor variables were initially assessed individually for an association with the dependent 156 
variable; presence of seizures (y/n), seizure number (during seven days prior to presentation), seizure 157 
length (minutes), serum creatinine concentration (µmol/L), age (years), sex (male or female), neutered 158 
status (neutered/entire), bodyweight (KG), time since seizure (hours), whether anti-convulsant 159 
medication was being administered at presentation and systolic BP (mmHg). For dogs recorded as 160 
having > 10 seizures within seven days of presentation, the seizure number was arbitrarily allocated to 161 
11. This allowed dogs with frequent seizures, but where owners were not certain of the exact number 162 
of seizures suffered, to be entered into the analysis. Those predictor variables demonstrating an 163 
association with the dependent variable with P < 0.2 in the univariable analysis were taken forward to 164 
the multivariable analysis. The multivariable linear regression analysis was performed with Log10 of 165 
cTnI concentrations obtained from all dogs (those with seizures and controls) as the dependent variable. 166 
Two sets of analyses were performed, one using concentrations obtained with the FG-cTnI assay and 167 
one using those from the hs-cTnI assay. The analysis was performed in a backward stepwise manner 168 
with the variable showing the highest p value excluded from the model at each step until all remaining 169 
variables had a p value less than 0.05. Final models were assessed for adequacy of fit using the adjusted 170 
R-square. The residuals of the final models were checked to confirm that they adequately met the model 171 
assumptions. Model assumptions were normality, linear relationship with an additive effect of the 172 
predictors, homoscedasticity and independence of the errors. The first assumption was checked using 173 
visual inspection of a histogram and normality tests of the residuals; to ensure the other assumptions 174 
were met the plots of the residuals were examined against fitted values and against their order in the 175 
dataset. 176 
Concentrations of cTnI obtained using the two different assays were correlated using a Spearman’s rank 177 
correlation and compared using Wilcoxon signed rank test. The latter analysis was performed using all 178 
values obtained from all dogs, including those with values ascribed at the limit of detection of the assay. 179 
The comparison was then repeated including only those animals where concentrations measured using 180 
both assays were above 0.02 ng/ml i.e. above the LOD of both assays. A Bland Altman plot of the 181 
difference in concentration obtained between the two assays plotted against the average of the two 182 
assays was made. 183 
For all analyses P values of ˂ 0.05 were accepted as statistically significant.  184 
Results 185 
Sixty dogs were enrolled, consisting of 30 dogs with seizures (group S) and 30 control dogs (group C). 186 
One dog with seizures was excluded from all statistical analyses except the comparison of cTnI 187 
concentrations obtained using the different assays as it had no BP, ECG and echocardiographic 188 
examination and therefore did not fully meet the entry criteria. Signalment and other baseline 189 
characteristics are summarised in Table 1. The distribution of breeds was different between groups 190 
(Table 1). Group S comprised 26 dogs with primary (idiopathic) epilepsy, two with brain tumours 191 
(suspected meningioma and suspected glioma), and one with necrotising meningoencephalitis. Three 192 
dogs had SE during the 24 hours before presentation, one of which required GA for seizure control. The 193 
median number of seizures in group S was two (range 1 – 11). The median seizure length was three 194 
minutes (Table 1). 195 
In group S, 17 dogs were taking anti-convulsants at presentation. Medications included phenobarbitone 196 
(Epiphen; Vetoquinol), levetiracetam (Keppra; UCB), potassium bromide (Epilease; Vet Plus Ltd), 197 
gabapentin (Neurontin; Pfizer) and diazepam (Diazepam Rectubes; Wockhardt UK). Other medications 198 
included oral antibiotics (n=1) and injectable dexamethasone (n=1) (Dexadreson; Intervet UK Ltd). No 199 
control dogs received medication. All but one of the dogs had normal ECGs and echocardiographic 200 
examinations. An echocardiographic abnormality was detected in one case in group S (mild left 201 
ventricular dilation) but this was attributed to the presence of sinus bradycardia (heart rate of 60 bpm). 202 
Repeat echocardiography performed three weeks later when the patient was in normal sinus rhythm 203 
(120 beats/minute) was unremarkable. 204 
Serum concentrations of cTnI (median [range]) were higher in dogs after a seizure compared to controls 205 
when measured by both assays (FG-cTnI assay, dogs with seizures median 0.07 [0.02-3.05] vs control 206 
dogs median 0.05 [0.02-0.13]ng/ml; p=0.014 (Figure 1) and hs-cTnI assay, dogs with seizures median 207 
0.03 [0.01-1.92] vs control dogs 0.02 [0.01-0.05]ng/ml; p<0.001. Seven dogs (1 with seizures and 6 208 
control dogs) had troponin concentrations at or below the LOD of the FG assay. 17 dogs (3 with seizures 209 
and 14 control dogs) had troponin concentrations at or below the LOD of the hs assay. As the 210 
distribution of troponin concentrations was skewed, logarithmic transformation was required in order 211 
to create a variable suitable for inclusion as the dependent variable in the univariable and multivariable 212 
analyses. The results of the simple linear regression with a single predictor are reported (Table 2). The 213 
final models of the multivariable linear regression analyses indicated that an increasing number of 214 
seizures (p<0.001) and increasing age (p<0.001) were significantly associated with higher 215 
concentrations of cTnI measured using both the FG-cTnI and hs-cTnI assays and both predictors had 216 
positive regression coefficients (Table 3). The adjusted R-square value was greater for the model in 217 
which concentrations obtained with FG-cTnI assay were used as the dependent variable (adjusted R-218 
square 0.48 with FG-cTnI assay and 0.44 with hs-cTnI assay). The residuals of the multiple regression 219 
analysis were normally distributed for the final model using FG-cTnI as the dependent variable but not 220 
for the final model using hs-cTnI. For these reasons the FG-cTnI model is the one for which the 221 
associations are reported.  222 
The troponin concentrations measured using the FG-cTnI assay correlated well with those values of the 223 
hs-cTnI assay r = 0.82 (p<0.001). However, the values obtained with the FG-cTnI assay were 224 
significantly higher than those obtained using the hs-cTnI assay. This was the case when data from all 225 
60 dogs was analysed and when only those 23 dogs for which values were greater than 0.02 ng/ml when 226 
measured by both assays were compared (P < 0.001 for both comparisons). The Bland Altman plot 227 
suggested that values obtained with the FG assay were consistently higher than those obtained with the 228 
hs assay (Figure 2).  229 
Discussion 230 
Our data show that dogs with generalized seizures have higher circulating serum cTnI concentrations 231 
compared with healthy control dogs. The results also indicate that the degree of troponin elevation is 232 
independently associated with number of seizures experienced and the patient’s age. These results are 233 
similar to those from a study of human patients which demonstrated that cTnI concentration increased 234 
with increased seizure number (Hajsadeghi et al. 2009). The presence of myocardial injury in the setting 235 
of seizure activity could be expected given the apnoea, tachycardia, increased myocardial oxygen 236 
consumption and excess catecholamine release associated with seizures which has been observed in 237 
experimental rat models (Metcalf et al. 2009). It is important to know that dogs which have recently 238 
experienced seizures may have elevated cTnI concentrations as seizures, which can be challenging to 239 
differentiate from syncope, are another cause of elevated cTnI in dogs without primary cardiac disease. 240 
A previous study suggested that serum cTnI is significantly higher in dogs following syncope compared 241 
with epilepsy in the absence of cardiac disease, although significant overlap compromised the 242 
diagnostic utility of cTnI for differentiation of these causes of episodic collapse (Dutton et al. 2016). 243 
The present study demonstrated similar findings in the dogs following seizures and, in addition that 244 
cTnI concentrations increase with increasing number of seizures and age.  These findings suggest that 245 
a diagnosis of cardiac syncope should not be based on cTnI alone and that further research is warranted 246 
in finding diagnostic tests which could help differentiate cardiac syncope from epileptic seizures 247 
(Dutton et al. 2016).  248 
Elevated cTnI concentrations may also be due to cardiac necrosis caused by catecholamines released 249 
directly into the myocardium via neural connections, as suggested by experimental models and studies 250 
on human patients with intracranial lesions (Burch et al. 1969, Kolin & Norris 1984, Shivalkar et al. 251 
1993). It is also possible that myocardial fibrosis, such as that shown to occur in human SUDEP patients, 252 
may occur particularly following repetitive autonomic stimulation, i.e. with an increased number of 253 
seizures (Earnest et al. 1992, Natelson et al. 1998). In humans, an increased number of seizures has 254 
been shown to be a risk factor for SUDEP (Lhatoo et al. 2015). It is therefore possible that an increasing 255 
number of seizures might be causative for increased myocardial injury, although further studies are 256 
necessary to investigate this possibility. As well as relevance to SUDEP, this is an argument for 257 
improved seizure control. 258 
In the population we describe, circulating cTnI concentrations increased with age consistent with 259 
previous canine studies (Oyama & Sisson 2004, Ljungvall et al. 2010, Hezzell et al. 2012). One possible 260 
cause is that in the aged heart, even in the absence of demonstrable cardiovascular disease, there is 261 
gradual loss of cardiac myocytes. The presence of troponin in the circulation may therefore represent 262 
myocyte death, or turnover, which may be a normal consequence of ageing (Oyama & Sisson 2004). 263 
Another possibility is decreasing renal clearance of troponin with increasing age. However, in this 264 
study, patients with chronic kidney disease (creatinine concentrations >150 µmol/L and USG <1.030) 265 
were excluded and no association between cTnI concentrations and creatinine was observed. Further 266 
studies are required to investigate why troponin concentrations are positively associated with age in the 267 
absence of renal dysfunction. Multivariable analysis adjusts the analysis for the effect of age and 268 
therefore the effect of seizure number is independent of the effect of age. 269 
We measured serum troponin I concentrations using two different assays generating similar results in 270 
the multivariable analyses. The FG-cTnI assay was able to detect cTnI in the serum of a greater 271 
proportion of the dogs with fewer results below the LOD of the assay, despite the assay having a higher 272 
limit of detection. The LOD reported for the FG-cTnI assay used in the current study was 0.02 ng/ml; 273 
this is lower than the LOD previously reported for this assay (Spratt et al. 2005). This was the LOD 274 
reported by the commercial laboratory that ran the analyses and chosen on the basis of good dilutional 275 
linearity of the assay down to concentration below 0.02 ng/ml demonstrated by the laboratory’s own 276 
validation studies (personal communication).  277 
The FG-cTnI assay demonstrated less clustering of values than those obtained with the hs-cTnI assay. 278 
Perhaps as a result of this the data obtained using the FG-cTnI assay resulted in a slightly higher R-279 
squared value for the final model using this as the dependent variable. Values obtained with the FG-280 
cTnI assay were significantly higher than the hs-cTnI values for the same patients. Explanations for 281 
higher cTnI values include different target amino acids for each analyser and differences in antibody 282 
specificity for free and complexed troponin (James et al. 2006). In human patients, various troponin 283 
assays have been compared and some were shown to be superior to others (James et al. 2006). Our 284 
study confirms that, despite close correlation, the two troponin assays cannot be used interchangeably. 285 
This has been shown in a previous veterinary study (Adin et al. 2006). The R-squared value indicates 286 
the proportion of the variance in the dependent variable that is predicted by the independent variables 287 
included in the model. In general, the higher the R-squared value, the better the model fits the data. The 288 
data obtained with the FG-cTnI assay resulted in a slightly higher R-squared value for the final model. 289 
It also better fulfilled the assumptions of the analysis with normally distributed residuals.   290 
In this study, a control population was included and patient numbers were higher than in a previously 291 
reported study on serum cTnI with seizures (Kim et al. 2012). A more homogenous population of dogs 292 
was included here, the majority suffering from primary (idiopathic) epilepsy. The other dogs included 293 
were also free of significant metabolic disease. The advantage of this being that the effect of variables 294 
such as seizure number and length can be analysed without underlying disease processes confounding 295 
the results. The disadvantage is that the effect of different types of underlying disease upon troponin 296 
concentration cannot be compared. As troponin concentrations can change with noncardiac disease, 297 
eliminating chronic kidney disease, immune-mediated haemolytic anaemia, sepsis, pyometra, 298 
respiratory disease and pancreatitis on history, clinical examination and blood tests was an important 299 
component of this study. 300 
This study has a number of limitations. None of the patients had myocardial biopsies, coronary 301 
angiography or post-mortem examinations to confirm myocardial cellular damage and rule out other 302 
possible causes of cTnI release. The cases presented here represent a referral population, which may 303 
differ from the population of dogs seen in general practice. The breed distribution of the control and 304 
seizure groups were different and the effect of breed on cTnI concentrations was not examined. This is 305 
unlikely to have had an effect on the overall findings but is a potential confounder. The results of the 306 
study only apply to the two troponin analysers used and the results cannot be used interchangeably. The 307 
effect of GA on troponin concentration was not assessed in this study, although only one patient required 308 
GA for seizure control, therefore had cTnI sampling delayed until 24 hours following GA. This same 309 
patient had the highest serum cTnI concentration in group S and had sinus bradycardia at 60 bpm. It is 310 
unclear whether the changes detected were a result of anti-epileptic medications, GA or a direct result 311 
of the high number of seizures. It is possible that the GA affected serum cTnI concentrations, resulting 312 
in elevated levels. However, two other epileptic patients also had elevated cTnI concentrations 313 
(according to the laboratory reference range) and yet did not require GA for seizure control. 314 
Interestingly, both patients suffered a high (> 10) number of seizures prior to blood sampling. Excluding 315 
the data of the one patient that underwent anaesthesia from the multivariable analysis did not 316 
substantially alter the results obtained. Further studies involving larger numbers of patients with 317 
seizures, pre- and post-GA, would be required to further investigate this association with serum cTnI 318 
concentrations. Finally, it is possible that in three dogs (two with brain tumours and one with necrotising 319 
meningoencephalitis) suffering seizures, that the underlying disease process may have had an effect on 320 
the serum troponin concentrations, rather than the seizures themselves affecting the results. Larger 321 
studies would be required to study the effects of individual disease processes on troponin concentrations 322 
as, so far, only individual case reports are available (Snyder et al 2010, Navarro-Cubas et al 2011). 323 
In conclusion, our results suggest that serum troponin concentrations are elevated in dogs with seizures 324 
when compared to healthy controls. The elevation is independently associated with number of seizures, 325 
when adjusted for the influence of age. The identification of elevated cTnI concentrations is important 326 
as it suggests that myocardial injury might occur secondary to seizure activity, which could have clinical 327 
implications for epileptic patients. In addition, the positive relationship between seizure number and 328 
serum cTnI concentration is likely to further reduce the diagnostic utility of serum cTnI for 329 
differentiation of syncope and seizure activity (Dutton et al. 2016). 330 
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Table 1. Baseline characteristics from both groups of dogs. 
 S  
(Seizure) 
n= 29 
N 
(normal controls) 
n=30 
Age (years).  4.0 (0.3-10.5) 4.4 (0.6-15.0) 
Male 16 (55%) 12 (40%) 
Neutered 18 (62%) 23 (77%) 
Bodyweight 
(KG). 
14.9 
(5.5-49.2) 
14.4 
(3.2-40.8) 
Serum Creatinine 
(umol/L). 
82 
(48-153) 
90 
(63-140) 
Systolic BP (mmHg). 
 
144 
(100-178) 
134 
(100-180) 
Breed Categories.  
Other pure breed 15 (52%) 5 (17%) 
Cross breed 1 (3.4%) 8 (27%) 
Labrador retriever 5 (17%) 4 (13%) 
Jack Russell terrier 1 (3.4%) 7 (23%) 
Staffordshire bull 
terrier 
3 (10%) 1 (3.3%) 
Cavalier King Charles 
spaniel 
2 (6.9%) 1 (3.3%) 
Border collie 2 (6.9%) 1 (3.3%) 
Springer spaniel 0 (0%) 3 (10%) 
Number of seizures 2 (1-11) NA 
Duration of seizures 
(minutes) 
3 (0.5-30) NA 
Interval between last 
seizure and sample 
collection (hours) 
36 (0-168) NA 
Receiving 
anticonvulsant 
medication 
17 (59%) 0 (0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 2. Results of Simple Linear Regression Analysis for log(FG-cTnI) (n=59). 
 
 
Variable 
 
(unit of measurement or comparator 
category) 
 
 
 
Coefficients 
B 
 
 
P - value 
95 % Confidence Interval for B 
Lower  Upper  
Seizure (no) -0.299 0.004 -0.499 -0.099 
Seizure number during 7 days prior 
to presentation 
0.086 < 0.001 0.056 0.116 
Seizure duration (minutes) 0.018 0.006 0.005 0.030 
Creatinine concentration (µmol/L) -0.002 0.449 -0.007 0.003 
Age (years) 0.049 0.003 0.018 0.079 
Sex (male) -0.051 0.640 -0.266 0.165 
Neuter (entire) 0.065 0.580 -0.168 0.298 
Weight (kg) 0.000 0.950 -0.010 0.009 
Time since last seizure (hours) -0.002 0.293 -0.005 0.002 
Medication (yes) 0.356 0.002 0.138 0.574 
Blood pressure (mmHg) 0.005 0.064 0.000 0.010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Results of Linear Regression Models for log(FG-cTnI) (n=59). 
  Confidence Intervals  
Coefficient  Lower 95% Upper 95% P - value 
log(FG-cTnI) Number of 
Seizures 
0.084 .057 .110 <0.001 
Adjusted R-square 
= 0.48 
Age (Years) 0.046 .022 .070 <0.001 
      
 Constant -1.507 -1.646 -1.367 <0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legend 
 
Figure 1. Box and whiskers plot showing serum cardiac Troponin I concentrations measured using the 
first generation assay in the dogs that had experienced seizures (n=29) and control dogs (n=30). The 
whiskers indicate the range of values obtained, the box extends from the 25th to the 75th percentile, the 
horizontal bar in the box represents the median. Concentrations were significantly higher (Mann-
Whitney; P = 0.014) in the dogs that had recently experienced seizures. Note the vertical axis is plotted 
on a logarithmic scale. 
 
 
  
Figure 2. A Bland-Altman plot comparing concentrations of cardiac troponin I obtained by the two 
assays. The difference in concentration obtained by subtracting the concentration obtained using the 
high-sensitivity (hs) assay from the concentration obtained using the first generation (FG) assay is 
plotted (on the vertical axis) against the average of the two concentrations obtained (on the horizontal 
axis). The plot illustrates a consistently positive difference which appears to increase in a near linear 
fashion suggesting that the concentrations obtained by the FG assay are always higher and by a 
consistent factor. Note the horizontal axis is discontinuous in order to include one data point with high 
concentrations. Bias has been shown as a horizontal dashed line. The upper and lower 95% limits of 
agreement are shown as dotted lines. 
 
 
